Eledon’s Tegoprubart Wins Orphan Drug Status for Liver Transplant Rejection Prevention
Event summary
- FDA granted Orphan Drug designation to tegoprubart for preventing allograft rejection in liver transplants.
- Tegoprubart previously received Orphan Drug designation for pancreatic islet cell transplantation and ALS treatment.
- Eledon plans to initiate an investigator-sponsored trial for liver transplantation later in 2026.
- Tegoprubart is an anti-CD40L antibody targeting immune modulation for organ transplants and ALS.
The big picture
Eledon’s Orphan Drug designation for tegoprubart in liver transplantation expands its pipeline beyond kidney transplants and ALS, positioning the company in a niche but high-value segment of organ transplant therapies. The designation underscores the FDA’s support for innovative treatments addressing unmet needs in rare diseases, potentially accelerating tegoprubart’s path to market.
What we're watching
- Clinical Validation
- Whether tegoprubart’s success in kidney transplants translates to liver transplants.
- Regulatory Momentum
- The pace at which Eledon secures additional designations for tegoprubart in other indications.
- Trial Execution
- How quickly Eledon initiates and completes the planned investigator-sponsored trial for liver transplantation.
Related topics